Erythropoietin dose and survival of hemodialysis patients

Authors

  • Mahdi Mohammadian Department of Social Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
  • Hamid Salehiniya Zabol University of Medical Sciences, Zabol, Iran
  • Salman Khazaei Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamedan, Iran
  • Abdollah Mohammadian-Hafshejani Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

DOI:

https://doi.org/10.15419/bmrat.v4i7.195

Keywords:

Bioloby, hemodialysis, Medicine, Erythropoietin

Abstract

Chronic kidney disease (CKD) is known as a major health problem worldwide (Levey et al., 2007). The CKD is defined as a stage of disease in which the patient's kidney function is less than a half of normal capacity (2). If the kidney function is 10% to 15% less than the normal capacity, the patient has reached the End Stage Renal Disease (ESRD). At this stage, the kidney transplant or dialysis with hemodialysis or peritoneal dialysis is necessary for patient's survival (Levey et al., 2002).

Author Biography

  • Mahdi Mohammadian, Department of Social Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
    amohamadii1361@gmail.com

Published

2017-07-28

Issue

Section

Letter to Editor

How to Cite

Erythropoietin dose and survival of hemodialysis patients. (2017). Biomedical Research and Therapy, 4(07), 1432-1434. https://doi.org/10.15419/bmrat.v4i7.195

Similar Articles

341-349 of 349

You may also start an advanced similarity search for this article.